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Summary A study was started in 1976 whereby patients with Stage II and operable Stage III MBC were
given adjuvant Tamoxifen for 1 year, increasing to 2 years from 1988. All patients had axillary nodal
involvement. Primary treatment consisted of a radical mastectomy or simple mastectomy with radiotherapy.
The rarity of the disease precluded a randomised trial. Thirty-nine patients are available for analysis at a
median follow-up of 49 months. The actuarial survival of the Tamoxifen treated patients is 61% (range
42-80%) at 5 years compared to 44% (range 35-53%) for historical controls (P = 0.006). Disease-free
survival was 56% (37-75%) vs 28% (17-33%) at 5 years (P = 0.005). There were no serious side-effects
recorded. The conclusion from this, the first reported series on adjuvant Tamoxifen therapy for MBC, is that
significant improvement in disease-free survival can be achieved with minimal upset to the patients. Recruit-
ment to the study continues.
The drug Tamoxifen has been used world-wide as adjuvant
therapy for carcinoma of the female breast. While individual
patients with male breast carcinoma (MBC) may have been
given adjuvant Tamoxifen, to the authors' knowledge, no
documented series has been published on the efficacy of the
drug used as adjuvant therapy in this group of patients. The
reason for this is probably the obvious one, the rarity of the
disease. Even with multi-centre co-operation it is unlikely
that sufficient patients would be available to carry out a
randomised clinical trial.
In a previous paper (Ribeiro, 1983), it was shown that a
37.5% objective regression rate had been obtained in the
treatment of advanced MBC with Tamoxifen. In a further
paper (Ribeiro, 1985), it was reported that oestrogen and
progesterone receptors had been measured in the primary
tumours of 16 patients by the dextran charcoal method
previously described by Barnes et al. (1977). Thirteen of the
16 primary tumours (81%) showed positive oestrogen or
progesterone activity.
Particularly poor survival rates ranging from 17% to 28%
have been reported for node positive MBC (Crichlow, 1974;
Yap et al., 1979).
For the reasons stated above it would seem reasonable to
prescribe adjuvant Tamoxifen therapy to patients with node
positive MBC. From 1976, it was proposed that all patients
with male breast carcinoma presenting with Stage II and
operable Stage III disease would be given adjuvant Tamoxi-
fen following definitive primary surgery. Stage I, inoperable
Stage III, and Stage IV patients were excluded. Patients were
entered into the study after the histology report was available
confirming that the axillary nodes were involved.
As a randomised clinical trial was not possible, actuarial
and disease-free survival of the patients, given adjuvant
Tamoxifen would be compared with historical controls,
allowing for the limitations of the conclusions that can be
drawn in the circumstances.
The present paper is an analysis of the first 39 patients
entered in the study between 1976 and 1988 inclusive. The
study is on-going and recruitment continues.
Materials and methods
All the patients entered in the study were referred to the
Christie Hospital, Manchester, England, following surgery
for male breast carcinoma.
The Staging classification is that used at The Christie
Hospital and based on the UICC classification of 1968. Stage
II patients would include those with TI, T2, NI, MO tumours
and Stage III, those with T3 NO, NI, MO tumours. All the
patients entered in the study had histologically proven
involvement of the ipsilateral axillary nodes.
Patients had the usual screening to exclude metastatic
disease. Investigations included, a full blood count,
biochemical profile, chest X-ray, and a limited skeletal
survey. If there was any doubt on the skeletal films, then a
bone scan was carried out. All these investigations were
shown to be negative before the patient was started on
Tamoxifen.
In addition, an hormonal profile was done on each patient,
which included serum levels of luteinising hormone (LH),
follicle stimulating hormone (FSH), oestradiol-17beta, test-
osterone, and more recently serum hormone binding globulin
(SHBG). The reference range for normal levels in males,
within the hospital were as follows: LH - 2 to 10IU 1',
FSH - 1 to 5 IU 1-, Oestradiol - <135 pmol 1', Tes-
tosterone - 10 to 30nmoll-l, and SHBG - 10 to
50 nmol 1'. These values fall within the range of other pub-
lished data on normal values for adult males (Baker et al.,
1976).
One of the patients exhibited the clinical characteristics of
Klinefelter's Syndrome and was found to have a 47 XXY
configuration on chromosome analysis.
Two of the patients had previously been treated for basal
cell carcinomata of the skin and one patient was successfully
treated for a squamous cell carcinoma of the lung, 4 years
previously, by means of a partial lobectomy.
Unfortunately hormone receptor assays were done on the
primary tumours of five paitents only. By using the dextran
charcoal method, four of the tumours were positive for both
oestrogen and progesterone receptors and one was negative.
The age of the youngest patient entered in the present
study was 39 years and the oldest patient 78 years, with a
mean of 62 years.
Nineteen of the patients were classified as having Stage II
disease and 20 as having Stage III disease.
Nine patients had a modified radical mastectomy carried
out and 30 had a simple (total) mastectomy with node samp-
ling of the axilla. All 30 patients who had a simple mastec-
tomy had postoperative radiotherapy to the chest wall and
regional lymph node areas. Three of the patients had a
radical mastectomy and post-operative radiotherapy.
The drug Tamoxifen was prescribed as Nolvadex D (ICI,
PLC.) in the dosage of 20 mg daily for a period of 1 year. At
the time ofthe start of this study, in 1976, this was the length
of time the drug was given to female patients. It also seemed
a reasonable period for the male patients who were in general
elderly and quite often on other general medication as well.
However in 1988, an Overview of 28 trials in which female
patients were given adjuvant Tamoxifen, was published
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(Early Breast Cancer Trialist's Collaborative Group, 1988).
In this report it was suggested that patients given adjuvant
Tamoxifen for 2 years or more had a better disease-free
survival than those given the drug for 1 year. It was therefore
proposed to give Tamoxifen to male breast patients entered
in the study from 1988 onwards, for a period of 2 years.
Statistics
Overall survival and disease-free survival curves were cal-
culated by the Kaplan-Meier method. Confidence intervals
were obtained by using Greenwood's formula (Armitage &
Berry, 1987). Curves were compared by using the logrank
test (Peto & Peto, 1972). Disease-free survival was measured
from the date adjuvant Tamoxifen was commenced to the
date when one of the following occurred; recurrence of breast
carcinoma on the chest wall or regional lymph nodes, or
distant metastases or censored time to death without evi-
dence of recurrence.
No patients was lost to follow-up. The shortest follow-up
was 12 months and the longest 135 months with a median of
49 months, the reason for this being that a substantial
number of patients have been entered into the study in the
last 3 years.
Figure 2 Disease free survival by year of treatment.
Results
Of the 39 patients given adjuvant Tamoxifen, two patients
stopped the drug due to side-effects; one patient developed
alopecia and the other a persistent skin rash. Seven patients
had their Tamoxifen therapy changed following relapse of
their disease. The remaining 30 patients completed their
course of adjuvant Tamoxifen without modification.
The measured hormonal profiles fell within the normal
ranges outlined above in all patients except the patient with
Klinefelter's Syndrome. The findings in the latter patient
were as follows: LH >32IU1 ', FSH >321U1-', oest-
radial < 100 pmol 1-', Testosterone 8.1 nmol 1-'.
The present status of the 39 patients is that 31 are alive,
five have died of breast cancer and three have died from
intercurrent non-malignant disease, with no recurrence of
breast cancer at the time of death.
The actuarial survival of all 39 patients was compared with
historical controls. The latter are patients with Stage II and
Stage III disease treated between 1942 and 1975 who did not
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Figure 1 Disease free survival adjuvant TAM vs controls.
receive adjuvant Tamoxifen. Only deaths from breast cancer
have been considered, patients dying from other causes being
censored. The actuarial suirvival at 5 years of the adjuvant
treated of the adjuvant treated patients is 61% (range 42% to
80%) vs 44% (range 35% to 53%) for the historical controls.
(P = 0.006). The disease-free survival of the adjuvant
patients was 56% (range 37% to 75%) at 5 years compared
to 25% (range 17% to 33%) for the controls (P = 0.0005) as
shown in Figure 1.
One of the major problems that exists when making com-
parisons with historical controls treated over a long period of
time is that the survival of the controls treated in the last
decade may be significantly better than that of the patients
treated three to four decades ago.
In Figure 2 is shown the disease-free survival of the 39
adjuvant Tamoxifen patients compared with patients treated
between 1942-59, 1960-69, and 1970-75. An attempt was
also made to match the control patients as far as possible
with the adjuvant Tamoxifen group with regard to age, stage,
and type of primary treatment.
The disease-free survival of the adjuvant Tamoxifen group
is not only significantly better than that of the patients
treated before 1970, but also better than that of the patients
treated after 1970 and not given adjuvant Tamoxifen (overall
chi-square = 11.78 on 3DF. P = 0.006).
Discussion
In Western Europe and in America, the majority of women
with breast cancer now present with Stage I disease. Further-
more, within that category, the tendency is to find more
primary tumours less than 2 cm in diameter when a National
screening programme is in place.
With all the publicity in relation to early detection in
breast cancer directed to the female population, it is not
surprising that the trend towards earlier presentation of
breast cancer in females, has not been mirrored in males.
Scheike (1973) in his series of 257 patients recorded 35%
as Stage I, 11% as Stage II and 42% as Stage III. In another
series of 301 cases (Ribeiro, 1985) the proportions were 38%
Stage I, 21% as Stage II and 26% as Stage III.
Adjuvant hormone and chemotherapy for node positive
breast cancer in females has been routinely prescribed for at
least 20 years. No series using adjuvant hormone therapy for
MBC has been published. The first report of the use of
adjuvant chemotherapy for node positive MBC appeared in
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1987 (Bagley et al., 1987). The report described the use of
adjuvant CMF in 20 patients with Stage II MBC, between
1974 and 1986; the median follow-up was 46 months. A
projected actuarial survival in excess of 80% was reported
for this series; the confidence limits were not stated but must
be considerable given the small number of patients. In fact
Bagley et al., did suggest caution in viewing these results as
the number of patients treated was small and the follow-up
time short.
Nevertheless, this achievement if real, is very substantial
when compared to previous reported survival data for node
positive patients with MBC. Crichlow (1974) in a summary
of eight studies found a 5-year survival rate of 28% for node
positive patients. Scheike (1974) reported a 5-year survival
rate of 38% for Stage II patients and 29% for Stage III. Yap
et al. (1979) were even more gloomy, finding a 5-year sur-
vival of just 17% for node positive patients.
On the other hand, Adami et al. (1985), looked at the long
term survival of 406 patients with MBC, diagnosed and
treated in Sweden between 1960 and 1978. They found a
consistent trend towards improved survival with the most
recently treated patients doing best. The 5-year survival rates
were 56% for the patients treated between 1960 and 1964,
62% for those treated from 1965-1969, and 72% for those
treated from 1970-1974. Apparently these trends in im-
proved survival for MBC, paralleled similar observations for
female breast cancer in Sweden.
One of the reasons for this improved survival rate put
forward by Adami et al., was that they treated fewer Stage
III and more Stage II patients in more recent years. Another
suggestion they made was that the most recently treated
patients might have included a more benign sub-group of
patients with a better prognosis. It is important to recognise
the latter possibility, when comparing the results of adjuvant
therapy with historical controls.
No additional knowledge was gained in the analysis of the
hormonal profile of the patients in this study. As stated
above, the profile was normal in all patients except the
patient with Klinefelter's Syndrome. Unfortunately he did
not have repeat profiles done before stopping Tamoxifen.
However, since this analysis was completed, two patients
with Klinefelter's Syndrome have been started on adjuvant
Tamoxifen. After 6 months of treatment, there has been no
alteration in their hormonal profiles.
In an earlier report (Ribeiro et al., 1980), serum oestradiol,
testosterone, FSH and LH estimations in ten patients with
MBC showed no significant difference from the estimations
done in 31 matched Controls.
More patients will have to be treated and a longer follow-
up is required before the roles of adjuvant endocrine and
chemotherapy can be compared and contrasted. However,
while it may be feasible to treat more patients, a longer
follow-up may be more problematical in an elderly group of
patients with a high rate of death from intercurrent disease in
the long term.
If, in the long term, there is no significant difference in
disease-free survival between CMF and Tamoxifen, then one
could suggest that Tamoxifen might be preferable for the
following reasons:
(1) Over 80% of patients with MBC have a positive oest-
rogen receptor status. The objective response of
advanced disease to Tamoxifen with minimal side-
effects has been well documented.
(2) The mean age of these patients is in the sixth decade.
They also have a number of intercurrent medical prob-
lems precluding the use of cytotoxic drugs in full
dosage.
(3) Tamoxifen does not produce any severe marrow toxi-
city and no drug induced mortality has been recorded.
It is, therefore, eminently suitable for use on a long
term basis.
The last indication is of particular interest in view of recent
reports (Breast Cancer Trials Committee, Scottish Cancer
Trials Office MRC 1987; Fisher et al., 1989) both of which
advocated adjuvant Tamoxifen given for 5 years to female
breast cancer patients as being more efficacious than Tamoxi-
fen given for for a shorter period. If these results are
confirmed, it might be within the bounds of reason to suggest
that node positive patients with MBC be given Tamoxifen
for an indefinite period following diagnosis of the disease.
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